Wednesday, 14 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 23, 2026

Target Just Posted Its First Sales Growth in 5 Quarters. So Why Did the Stock Drop Anyway?

View original at finance.yahoo.com
Target Just Posted Its First Sales Growth in 5 Quarters. So Why Did the Stock Drop Anyway? Shares of big-box retailer Target(NYSE: TGT) slid about 4% after the company reported its fiscal first quarter of 2026 (the period ended May 2, 2026) earlier this week…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Excluding the ~$0.97/share one-time legal settlement gain from Q1 FY2025, adjusted prior-year EPS was approximately $1.30, making Q1 FY2026 EPS of $1.71 represent approximately 32% year-over-year growth.

    60% confidence

  • Business momentum in Q1 FY2026 was broad-based: all six core merchandise categories grew, store traffic rose 4.4%, digital comparable sales jumped 8.9%, and higher-margin non-merchandise revenue grew nearly 25%.

    60% confidence

  • Target will make more changes to what it sells and how it sells it in 2026 than has been seen in a decade.

    60% confidence

  • Comparable sales rose 5.6% in Q1 FY2026, Target's first positive comparable-sales reading in five quarters and its strongest comparable-sales gain in approximately four years.

    60% confidence

Data points we hold from this source

Target Corporation · net income781 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com